Insight

May 28, 2024, 04:25

Arndt Vogel: A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas

Arndt Vogel shared on X:

“A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas, European Journal of Cancer.

Stopped at IA due to futility.
Comparable activity, safety manageable.
Not good, but both are options in 2nd line.”

Captem

Additional information.
Source: Arndt Vogel/X

Arndt Vogel is a managing senior consultant and professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School.

He is the Head of the GI-Cancer Center and of the Center for Personalized Medicine at Medical School Hannover and chairs the Hepatobiliary Cancer Study Group of the AIO, a collaborative group in clinical oncology in Germany. His scientific focus is translational and clinical research in gastrointestinal cancer.

A. Bongiovanni Arndt Vogel B. Rudnas C. Liverani cancer CAPTEM D. Santini European Journal of Cancer F. Bergamo F. Foca F. Gelsomino F. Pucci F. Recine F. Spada FOLFIRI G. Badalamenti G. Di Meglio Hannover Medical School I. Lolli L. Antonuzzo M. Cives M. Tebaldi M.P. Brizzi N. Ranallo neuroendocrine carcinomas O. Nanni OncoDaily Oncology R. Berardi R. Marconcini S. Leo S. Pusceddu S. Severi S. Tamberi S. Vanni

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage